Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297721192> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W4297721192 endingPage "211" @default.
- W4297721192 startingPage "207" @default.
- W4297721192 abstract "The main aim of present work is to identification of potency of novel quinoline-4-one derivatives as a factor Xa inhibitors by in-silico ADME study and molecular docking study. Factor Xa is enzyme which play major role in blood coagulation process by conversation of prothrombine to thrombine. Thrombine is the protein which converts fibrinogen to fibrin (clot). Inhbition of factor Xa is altimetly inhbition of blood coagulation process. Due to the abnormal blood coagulation, serious to very serious problems can create and will lead to death. Betrixaban, Rivaroxaban, Epixaban and Edoxaban which are FDA approval dugs as factor Xa inhibitors. They are very potent drugs and very few side effects compare to other available anti-coagulating drugs so they was taken as a reference molecules for current study. Some novel quinoline-4-one derivatives was design and screened for factor Xa enzyme. We design 26 compounds and first they screen for in-silico ADME parameters. Very few compounds not pass Lipinski rule. A majority compound shows excellent in-silico ADME properties. In molecular docking study almost all compound shows near binding energy to reference drug and shows almost near dock score. Q23 and Q26 show excellent inhibitory activity against Factor Xa. 13 molecules shows very near dock score compare to reference drugs. This study became a reference and provides valuable data for the synthesis, in-vitro and in-vivo evaluation of quinolone-4-on derivatives as Factor Xa inhibitors." @default.
- W4297721192 created "2022-09-30" @default.
- W4297721192 creator A5066039047 @default.
- W4297721192 creator A5088384183 @default.
- W4297721192 date "2022-08-12" @default.
- W4297721192 modified "2023-10-16" @default.
- W4297721192 title "Design, in-silico ADME Study and molecular docking study of novel quinoline-4-on derivatives as Factor Xa Inhibitor as Potential anti-coagulating agents" @default.
- W4297721192 cites W1653739410 @default.
- W4297721192 cites W1707073606 @default.
- W4297721192 cites W1989154071 @default.
- W4297721192 cites W2003726612 @default.
- W4297721192 cites W2101669068 @default.
- W4297721192 cites W2158902152 @default.
- W4297721192 cites W2283289193 @default.
- W4297721192 cites W2401446526 @default.
- W4297721192 cites W2767506126 @default.
- W4297721192 cites W2778783388 @default.
- W4297721192 cites W2781313778 @default.
- W4297721192 cites W2792975473 @default.
- W4297721192 cites W2796461648 @default.
- W4297721192 cites W2801771295 @default.
- W4297721192 cites W2804051595 @default.
- W4297721192 cites W2905919131 @default.
- W4297721192 cites W3012323241 @default.
- W4297721192 cites W3015292534 @default.
- W4297721192 cites W3024102726 @default.
- W4297721192 doi "https://doi.org/10.52711/2231-5691.2022.00034" @default.
- W4297721192 hasPublicationYear "2022" @default.
- W4297721192 type Work @default.
- W4297721192 citedByCount "1" @default.
- W4297721192 countsByYear W42977211922023 @default.
- W4297721192 crossrefType "journal-article" @default.
- W4297721192 hasAuthorship W4297721192A5066039047 @default.
- W4297721192 hasAuthorship W4297721192A5088384183 @default.
- W4297721192 hasConcept C104317684 @default.
- W4297721192 hasConcept C112516734 @default.
- W4297721192 hasConcept C159110408 @default.
- W4297721192 hasConcept C185592680 @default.
- W4297721192 hasConcept C203014093 @default.
- W4297721192 hasConcept C2775905019 @default.
- W4297721192 hasConcept C2777292125 @default.
- W4297721192 hasConcept C2780035454 @default.
- W4297721192 hasConcept C41685203 @default.
- W4297721192 hasConcept C41847442 @default.
- W4297721192 hasConcept C55493867 @default.
- W4297721192 hasConcept C69366308 @default.
- W4297721192 hasConcept C71924100 @default.
- W4297721192 hasConcept C89560881 @default.
- W4297721192 hasConcept C98274493 @default.
- W4297721192 hasConceptScore W4297721192C104317684 @default.
- W4297721192 hasConceptScore W4297721192C112516734 @default.
- W4297721192 hasConceptScore W4297721192C159110408 @default.
- W4297721192 hasConceptScore W4297721192C185592680 @default.
- W4297721192 hasConceptScore W4297721192C203014093 @default.
- W4297721192 hasConceptScore W4297721192C2775905019 @default.
- W4297721192 hasConceptScore W4297721192C2777292125 @default.
- W4297721192 hasConceptScore W4297721192C2780035454 @default.
- W4297721192 hasConceptScore W4297721192C41685203 @default.
- W4297721192 hasConceptScore W4297721192C41847442 @default.
- W4297721192 hasConceptScore W4297721192C55493867 @default.
- W4297721192 hasConceptScore W4297721192C69366308 @default.
- W4297721192 hasConceptScore W4297721192C71924100 @default.
- W4297721192 hasConceptScore W4297721192C89560881 @default.
- W4297721192 hasConceptScore W4297721192C98274493 @default.
- W4297721192 hasLocation W42977211921 @default.
- W4297721192 hasOpenAccess W4297721192 @default.
- W4297721192 hasPrimaryLocation W42977211921 @default.
- W4297721192 hasRelatedWork W188266097 @default.
- W4297721192 hasRelatedWork W2804603998 @default.
- W4297721192 hasRelatedWork W3029350203 @default.
- W4297721192 hasRelatedWork W3113194108 @default.
- W4297721192 hasRelatedWork W3127851518 @default.
- W4297721192 hasRelatedWork W4283030826 @default.
- W4297721192 hasRelatedWork W4319349685 @default.
- W4297721192 hasRelatedWork W4363678021 @default.
- W4297721192 hasRelatedWork W4385428583 @default.
- W4297721192 hasRelatedWork W4385441743 @default.
- W4297721192 isParatext "false" @default.
- W4297721192 isRetracted "false" @default.
- W4297721192 workType "article" @default.